MHRA Regulatory Flexibilities Resulting from Coronavirus (COVID-19)

On 4 August 2020 the UK MHRA updated the guidance for industry on flexible approaches to regulations taken during the COVID-19 outbreak.

Regulatory flexibilities do not displace or diminish any other obligations applicable to the relevant products. Any medicinal product which benefits from these regulatory flexibilities remains subject to marketing authorisation.

These regulatory flexibilities are:

  • temporary and will be kept under review
  • offered to protect people‚Äôs health in exceptional circumstances
  • effective immediately
Read more online 
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /